Avantax Advisory Services, Inc. Moderna, Inc. Transaction History

Avantax Advisory Services, Inc.

$14.9 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$101.21 - $166.61 $86,939 - $143,117	859 Added 17.06%	5,894 $699,000
Q1 2024 May 08, 2024	BUY	$85.37 - $115.44 $149,397 - $202,020	1,750 Added 53.27%	5,035 $536,000
Q4 2023 Feb 07, 2024	SELL	$69.51 - $104.43 $180,169 - $270,682	-2,592 Reduced 44.1%	3,285 $326,000
Q3 2023 Nov 07, 2023	BUY	$96.41 - $126.61 $1,060 - $1,392	11 Added 0.19%	5,877 $607,000
Q2 2023 Aug 11, 2023	SELL	$118.5 - $160.53 $19,315 - $26,166	-163 Reduced 2.7%	5,866 $712,000
Q1 2023 Apr 28, 2023	SELL	$135.66 - $197.02 $18,992 - $27,582	-140 Reduced 2.27%	6,029 $925,000
Q4 2022 Feb 13, 2023	SELL	$118.38 - $210.04 $193,551 - $343,415	-1,635 Reduced 20.95%	6,169 $1.11 Million
Q3 2022 Nov 01, 2022	BUY	$118.07 - $194.18 $19,363 - $31,845	164 Added 2.15%	7,804 $923,000
Q2 2022 Aug 02, 2022	BUY	$117.13 - $176.59 $301,961 - $455,249	2,578 Added 50.93%	7,640 $1.09 Million
Q1 2022 Apr 27, 2022	SELL	$126.46 - $235.05 $25,797 - $47,950	-204 Reduced 3.87%	5,062 $874,000
Q4 2021 Jan 24, 2022	SELL	$225.82 - $368.51 $189,237 - $308,811	-838 Reduced 13.73%	5,266 $1.34 Million
Q3 2021 Oct 21, 2021	BUY	$221.9 - $484.47 $45,489 - $99,316	205 Added 3.48%	6,104 $2.35 Million
Q2 2021 Jul 29, 2021	BUY	$129.91 - $234.98 $4,416 - $7,989	34 Added 0.58%	5,899 $1.39 Million
Q1 2021 May 13, 2021	SELL	$109.18 - $185.98 $33,736 - $57,467	-309 Reduced 5.0%	5,865 $770,000
Q4 2020 Jan 22, 2021	SELL	$65.74 - $169.86 $67,580 - $174,616	-1,028 Reduced 14.27%	6,174 $642,000
Q3 2020 Oct 14, 2020	BUY	$54.34 - $94.85 $391,356 - $683,109	7,202 New	7,202 $511,000

Others Institutions Holding MRNA

# of Institutions

954

Shares Held

241M

Call Options Held

10.6M

Put Options Held

18.7M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.

Account